Regarding its precise anorectic and immune checkpoint functions, anti-obesity drugs have been developed by exploiting its activating effects, such as GDF15 analogs and GFRAL receptor agonists. Here, GDF15 is linked to obesity due to melanocortin 4 receptor deficiency.